Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human, Open-Label, Dose Escalation and Expansion Trial of BTX-9341 in Participants With Advanced and/or Metastatic Breast Cancer

NCT06515470 is registered in ClinicalTrials.gov with Biotheryx, Inc. as lead sponsor.

NCT NCT06515470
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06515470 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human, Open-Label, Dose Escalation and Expansion Trial of BTX-9341 in Participants With Advanced and/or Metastatic Breast Cancer
Lead sponsor
Biotheryx, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
July 3, 2024
Completion date
December 31, 2027
Enrollment
82 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer